Ataluren

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Amino Acid Metabolism, Inborn Errors

Conditions

Amino Acid Metabolism, Inborn Errors

Trial Timeline

Jul 19, 2010 → Nov 3, 2011

NCT ID

NCT01141075

About Ataluren

Ataluren is a phase 2 stage product being developed by Sanofi for Amino Acid Metabolism, Inborn Errors. The current trial status is terminated. This product is registered under clinical trial identifier NCT01141075. Target conditions include Amino Acid Metabolism, Inborn Errors.

What happened to similar drugs?

1 of 1 similar drugs in Amino Acid Metabolism, Inborn Errors were approved

Approved (1) Terminated (1) Active (0)

✅AcetaminophenJohnson & JohnsonApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01141075	Phase 2	Terminated	Jul 19, 2010	Nov 3, 2011	Amino Acid Metabolism, Inborn Errors
NCT00947193	Phase 2	Terminated	Oct 14, 2009	Aug 30, 2011	Hemophilia A
NCT00847379	Phase 2	Terminated	Jan 31, 2009	May 24, 2010	Duchenne Muscular Dystrophy
NCT00759876	Phase 2	Terminated	Aug 13, 2008	May 17, 2010	Duchenne Muscular Dystrophy

Competing Products

4 competing products in Amino Acid Metabolism, Inborn Errors

See all competitors

Product	Company	Stage	Hype Score
Acetaminophen	Johnson & Johnson	Approved	35
Intravenous infusion of N-acetylcysteine + Intravenous infusion of Fomepizole (4-MP)	Johnson & Johnson	Phase 2	27
AAV2-hAADC	PTC Therapeutics	Phase 2	32
gene therapy	PTC Therapeutics	Phase 1/2	47